Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PFE has clawed back the prior week's losses, gaining 3.2% to $28.37, with earnings now thirteen days away and the analyst community turning incrementally more confident on price targets even as the consensus rating stays neutral.
JP Morgan's Chris Schott raised his target to $30 from $28 on October 9, the most recent bellwether move and a reversal of his own cut in July. That follows Scotiabank lifting to $33 from $30 on October 6 and HSBC moving to $30 from $28 in September. The direction has clearly shifted. Three raises in five weeks contrasts sharply with the July wave, when JPMorgan, BofA, BMO Capital and Guggenheim all trimmed targets while keeping ratings intact. The mean Street target is now $29.26, a slim but real premium to the current price. Bulls point to $60 billion in annual sales, a broad international revenue base and a forward EPS trajectory that ORTEX factor scores rank in the 88th percentile year-on-year. Bears remain focused on gross-to-net adjustments on Vyndaqel and Ibrance squeezing reported revenue, a risk the market may still be underpricing. The P/E has expanded to 9.8x over the past month, and EV/EBITDA runs at 8.9x, both drifting higher as the stock recovers.
Short interest and positioning tell a quiet story. Short interest has fallen 2.4% on the week to 2.6% of the free float, a low and declining level that generates no particular squeeze or crowding narrative. Borrowing costs run at 0.39%, near the bottom of their recent range, and borrow availability is effectively unconstrained, more shares available than the entire short book requires by a multiple that makes the lending market a non-event. Options positioning is similarly inert: the put/call ratio at 0.75 is almost exactly in line with its 20-day average of 0.74, a z-score of 0.07, well inside the range that would signal directional conviction either way. Nothing in the borrow or options market is loading up ahead of the print.
The insider buying cluster from August remains the clearest conviction signal on the stock. CEO Albert Bourla bought 38,000 shares at $26.34 on August 12 in an open-market purchase, not under a 10b5-1 plan. Director Ronald Blaylock added roughly 39,000 shares the same week at $25.46, and Director Mortimer Buckley bought 37,600 shares at $25.52. Net insider buying over the 90 days to September 30 was approximately 111,600 shares with a dollar value near $2.9 million. All three purchases were discretionary and came when the stock was trading well below its current level.
Medicaid data from the Centers for Medicare and Medicaid Services adds a cautionary note on volume trends. Medicaid units reimbursed for Pfizer products were down 17% against Q1 last year, and Medicaid prescriptions were down 21% over the same comparison period. Neither dataset has a measured lead to the company's reported financials in ORTEX's Alt Data layer, so these cannot be read as a forecast of the October 27 print. They do, however, give some texture to the bear case on rebate and volume pressure that analysts have flagged repeatedly since July.
Among correlated peers, BMY fell 4.9% on the week and MRK was broadly flat. Pfizer's outperformance was not driven by any single catalyst, leaving the October 27 print as the next clean test of whether the Street's gradually improving targets are supported by the underlying business.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
